EDSS

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, July 28, 2022
Class Action Lawsuit, Professional Services, Legal, ATRA, EDSS, Ethics, IA, Data, Atara, NASDAQ, News, Certification, Company, Suite, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Atara issued a press release on July 12, 2022, updating the market on its preliminary analysis phase 2 EMBOLD study for product candidate ATA188.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc.

Retrieved on: 
Wednesday, July 27, 2022
ATRA, Awareness, Industry, EDSS, Telephone, IA, Data, WHY, Levi, Atara, NASDAQ, Disability, Company, Patient, Pharmaceutical industry

New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.

Key Points: 
  • New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .
  • Then, on February 28, 2022, Atara issued a press release attached to their Form 8-K, providing an update on ATA188.

Rune Labs Partners with Coastal Research Institute to Identify Biomarkers of Multiple Sclerosis Lesions using AI Platform to Analyze Patient Neurophysiological Data

Retrieved on: 
Thursday, July 14, 2022
Eclipse, Technology, Disease, EDSS, Nerve, José Benito Vives de Andréis Marine and Coastal Research Institute, Leadership, Neuropathic pain, Multiple sclerosis, Patient, CRI, Spine, SAN, Demyelinating disease, MD, Brain, Physician, Runes, Parkinson's disease, Pathology, Spinal cord, Machine learning, Trial of the century, Therapy, Remyelination, Standard electrode potential, Data analysis, MS, Research, Immune system, Degenerative disease, Physiology, Doctor of Philosophy, Software, Institute, Biomarker, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, July 14, 2022 /PRNewswire/ -- Rune Labs, a precision neurology software and data platform company, today announced it is enrolling patients with multiple sclerosis (MS) in a study to identify neurophysiological biomarkers of the disease. The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology. Demyelination is a hallmark symptom of MS that occurs when the immune system attacks nerve fibers, causing lesions in the brain and spine. 

Key Points: 
  • The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology.
  • Clinical scores currently used as endpoints and screeners in trials are imprecise and do not always correlate with lesion activity.
  • "Rune's AI platform enables us to take raw brain data and convert it into actionable biomarkers of myelination."
  • Rune Labs' first-in-class precision neurology software platform uses machine learning to capture and analyze electrophysiological brain data to uncover previously overlooked markers of disease.

Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Retrieved on: 
Tuesday, July 12, 2022
Oncology, Health, Biometrics, Other Health, General Health, Clinical Trials, Biotechnology, EDSS, SEC, Security (finance), Safety, Canadian Aviation Regulations, EDT, U.S. Securities and Exchange Commission, EBV, Result, Interim analysis, Biology, System Independent Data Format, Intention, Epstein–Barr virus, Particle-size distribution, LinkedIn, Securities Act of 1933, Company, Lymphatic system, Multiple sclerosis, Northwest Biotherapeutics, Securities Exchange Act of 1934, Patient, Form, Review, Investor, COVID-19, Analysis, Data, Autoimmune disease, ATRA, HLA, Financial condition report, IA, Nasdaq, Form 10-K, Degenerative disease, Media, MTR, MS, Antigen, FDA, Research, Twitter, TCR, Cancer, Hematological Cancer Research Investment and Education Act, ID, Pharmaceutical industry, Medical imaging

The IA was planned to occur before enrolling patient 80 to enable an increased sample size if needed.

Key Points: 
  • The IA was planned to occur before enrolling patient 80 to enable an increased sample size if needed.
  • The IDSMC believes the six-month interim endpoint may be an inaccurate measure of the potential of this intervention in this condition.
  • The IDSMC recommended continuing the study without sample size adjustment until the final analysis of the primary endpoint of confirmed EDSS improvement at 12 months.
  • Following the EMBOLD IA, we are proceeding with the IDSMCs recommendation that the study continue to completion without sample size adjustment, said Jakob Dupont, M.D., Head of Global Research & Development at Atara.

OM1 LAUNCHES A NEW ESTIMATION MODEL FOR THE EXPANDED DISABILITY STATUS SCORE (EDSS) FOR MULTIPLE SCLEROSIS PATIENTS

Retrieved on: 
Thursday, June 23, 2022
Cloud, Depression, Autoimmunity, Inflammation, Patient, Mental health, Hypoesthesia, Data set, Diagnosis, Expanded Disability Status Scale, Paper, CNS, Time, Multiple sclerosis, Fatigue, RWD, Research, Machine learning, Muscle weakness, MLP, Multiple Sclerosis Journal, EDSS, Lists of diseases, OM1, Conditional sentence, Spasticity, Severe cognitive impairment, Dizziness, MS, Database, SAGE Publishing, Central nervous system, Pharmaceutical industry, Medical imaging

BOSTON, June 23, 2022 /PRNewswire/ -- OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the publication of their validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis in the Multiple Sclerosis Journal by Sage Publications.

Key Points: 
  • Scores can help determine the course of illness, need for different levels of care, and help guide treatment decisions.
  • Nearly 1 million Americans suffer from MS. With no cure, delay in diagnosis and treatment can result in permanent disability.
  • Once diagnosed, clinicians use the Expanded Disability Status Score (EDSS) to evaluate and measure disability levels in MS patients.
  • For this study, OM1 extrapolated data from the OM1 PremiOM MS Dataset to amplify and expand existing clinician rated EDSS scores.

REDEFINING THE LUXURY CROSSOVER THAT LAUNCHED A SEGMENT: THE ALL-NEW 2023 LEXUS RX

Retrieved on: 
Wednesday, June 1, 2022
Caviar, Dark, RX, Education, Interior, PCS, Electrification, Black Cascade, Lexus RX, LDA, Traction, Rigidity, The White Pearl, Human, HUD, AWD, Acceleration, Digital, GA, Lexus, Hybrid (biology), Lens, EDSS, Torque, Safety, Technology, Sale, Drawn to Life: The Next Chapter (Nintendo DS video game), PHEV, Mark (given name), Macadamia, Cassette tape, Cryptocurrency, Electric motor, Iridium, Premium

Today, Lexus redefined what the RX means to guests with the global reveal of the all-new RX at the Lexus New Product Showcase.

Key Points: 
  • Today, Lexus redefined what the RX means to guests with the global reveal of the all-new RX at the Lexus New Product Showcase.
  • The 2023 Lexus RX, the fifth generation for the Lexus core model, is completely redesigned from the wheels to the roof rails, featuring a new global platform, two all-new grades, available Digital Key, Lexus Safety System+ 3.0 and Lexus Interface Multimedia System.
  • The 2023 RX builds on the foundation of the iconic Lexus spindle design and evolves into a new, cohesive spindle body design.
  • The 2023 RX will be offered in six grades: Standard, Premium, RX-first Premium+, Luxury, F SPORT Handling and RX-first F SPORT Performance.

Mapi Pharma to Present Late Breaking Poster Presentation on GA Depot for Treating Primary Progressive Forms of Multiple Sclerosis at CMSC 2022 Annual Meeting

Retrieved on: 
Tuesday, May 31, 2022
Diabetes, LCM, CEO, API, RMS, Remyelination, RRMS, National Harbor, Maryland, Woman, CDP, Poster, NASDAQ, Phase, EDSS, GA, NESS, CMSC, Patent, Convention center, Time, NEP, MS, Gaylord National Resort & Convention Center, Man, Multiple sclerosis, Safety, Chief executive officer, Glatiramer acetate, GLOBE, Pharmaceutical industry, PPMS, Patient, Viatris

GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa).

Key Points: 
  • GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa).
  • GA Depot consists of extended-release microspheres containing GA, administered intramuscularly (IM) once every 28 days.
  • Mapi Pharma partnered with Viatris (NASDAQ: VTRS) for GA Depot in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis.
  • Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

Retrieved on: 
Tuesday, May 31, 2022
Google Images, Magnetic resonance imaging, MRI, SPMS, Goto, De novo, Literature, Self-test of intelligence, EMB Consultancy, Sclerosis, Quality of life, Clinical trial, Algorithm, Neurodegeneration, Brain, Alzheimer's disease, EDSS, Multiple sclerosis, DC, Frontotemporal dementia, PPMS, Eye, RRMS, Eye movement, GMB (trade union), IVD, Robotics, MCRA, Elective surgery, McGill University, Partnership, General surgery, Spine, Consultant, Parkinson's disease, Neuroscience, Patient, Neurology, Industry, Urology, Minuteman Library Network, Biomarker, Contract research organization, CRO, Technology, HIV disease progression rates, HIPAA, Intelligence, Diagnosis, Medical device, CEO, Medical imaging

"Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.

Key Points: 
  • "Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.
  • However, this technology was complex to use, expensive, and the data collected did not allow clinicians to benefit from it for their patients.
  • Up until now, with current standard of care in MS, several years are usually required before clinicians confidently establish the presence of disease progression.
  • www.innodemneurosciences.com
    MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

Retrieved on: 
Tuesday, May 31, 2022
CEO, Google Images, Consultant, Parkinson's disease, PPMS, Eye, Neuroscience, RRMS, Partnership, Magnetic resonance imaging, Eye movement, Patient, MRI, GMB (trade union), SPMS, Sclerosis, IVD, Quality of life, Neurology, Clinical trial, Robotics, MCRA, Algorithm, Goto, McGill University, Neurodegeneration, Brain, Elective surgery, Industry, Urology, De novo, Literature, Minuteman Library Network, Biomarker, Contract research organization, Alzheimer's disease, Self-test of intelligence, CRO, EDSS, General surgery, Multiple sclerosis, Technology, HIV disease progression rates, HIPAA, Intelligence, Spine, EMB Consultancy, Diagnosis, DC, Medical device, Frontotemporal dementia, Medical imaging

"Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.

Key Points: 
  • "Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.
  • However, this technology was complex to use, expensive, and the data collected did not allow clinicians to benefit from it for their patients.
  • Up until now, with current standard of care in MS, several years are usually required before clinicians confidently establish the presence of disease progression.
  • www.innodemneurosciences.com
    MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA

Retrieved on: 
Saturday, May 28, 2022
Serum, National Medical Products Administration, Neuromyelitis optica spectrum disorder, Center for Drug Evaluation and Research, B-ALL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, IIT, Aquaporin, Degenerative disease, Patient, Woman, Quality of life, Severe cognitive impairment, Visual acuity, Expanded Disability Status Scale, Paralysis, End organ damage, Lymphatic system, NMO, Hope, FDA, SAN, Nervous system, IND, Industry, CDE, Center, EDSS, Human, Defecation, Physical disorder, NMPA, Safety, CRS, Central nervous system, PD, Animal, CAR, BCMA, Prevalence, CD19, Visual impairment, Frost & Sullivan, Growth, ODD, Pharmaceutical industry, Vaccine, NMOSD

This NMPA acceptance, the world's first IND application for CAR-T in NMOSD.

Key Points: 
  • This NMPA acceptance, the world's first IND application for CAR-T in NMOSD.
  • IASO Bio's IND application is based on the Equecabtagene AutoleucelInvestigator Initiated Trial (IIT) enrolling patients with refractory NMOSD who were positive for Aquaporin 4 antibodies (AQP4).
  • Subjects enrolled were patients with poor symptom control despite at least one year of treatment with at least one immunosuppressant.
  • "Theuse of CAR-T cell products has been widely accepted in the treatment of hematologic malignancy but has been rarely reported in the treatment of autoimmune diseases.